Clementia Pharmaceuticals

Clementia is a biopharmaceutical company dedicated to bringing effective new treatments to people who have none.
We are rapidly developing our first lead product candidate, palovarotene, to treat fibrodysplasia ossificans progressiva (FOP), an ultra-rare and severely disabling disorder, and other diseases.

We believe that palovarotene holds significant potential for individuals with FOP and are currently investigating the oral compound in Phase 2 clinical trials. We strive to work with bold efficiency and hand-in-hand with physicians and disease communities to chart a new course in drug development.

TypeSubsidiary
Parent CompanyIpsen
HQMontréal, CA
Founded2012
Websiteclementiapharma.com
Clementia Pharmaceuticals was founded in 2012 and is headquartered in Montréal, CA

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Clementia Pharmaceuticals

Clarissa Desjardins

Clarissa Desjardins

CEO and Founder
Jeff Packman

Jeff Packman

Chief Development Officer
James M. Roach

James M. Roach

Executive Vice President, Research and Development
Nabil A. Abadir

Nabil A. Abadir

Executive Vice President, Global Head of Medical & Scientific Affairs
Donna Grogan

Donna Grogan

Chief Medical Officer
Show more

Clementia Pharmaceuticals Office Locations

Clementia Pharmaceuticals has offices in Montréal and Newton
Montréal, CA (HQ)
1000 De La Gauchetière, 1000 Rue de la Gauchetière O #1200
Newton, US
Riverside Center, 275 Grove St Suite 2 - 400, Auburndale
Show all (2)

Clementia Pharmaceuticals Financials and Metrics

Summary Metrics

In total, Clementia Pharmaceuticals had raised $92.5 m. Clementia Pharmaceuticals is a subsidiary of Ipsen

Clementia Pharmaceuticals Revenue

USDFY, 2014FY, 2015FY, 2016

General and administrative expense

2.3m5.5m3.4m

R&D expense

7.6m14.2m16.7m

Operating expense total

9.8m19.7m20.1m

Interest expense

12.9m56.1m37.6m
USDFY, 2014FY, 2015FY, 2016

Cash

5.5m58.1m9.4m

Accounts Receivable

367.2k424.3k30.5m

Current Assets

6.9m59.6m40.6m

PP&E

10.6k45.3k38.2k
USDFY, 2014FY, 2015FY, 2016

Net Income

(12.3m)(75.9m)(57.5m)

Depreciation and Amortization

135.8k148.8k172.6k

Accounts Payable

1.0m2.1m505.0k

Cash From Operating Activities

9.7m17.6m18.8m
Show all financial metrics

Clementia Pharmaceuticals Operating Metrics

FY, 2016

Clinical Programs

4

Phase II Patients Enrolled

40
Show all operating metrics

Clementia Pharmaceuticals Online and Social Media Presence

Embed Graph

Clementia Pharmaceuticals News and Updates

Clementia Pharmaceuticals Inc. Announces Receipt of Final Court Approval for Plan of Arrangement With Ipsen S.A.

MONTREAL, April 11, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that the Québec Superior Court issued earlier today a final order approving the previously announced statutory plan of arrangement under the Canada B…

Clementia Pharmaceuticals Inc. Shareholders Approve Plan of Arrangement With Ipsen S.A.

MONTREAL, April 09, 2019 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA) ("Clementia" or the "Corporation") is pleased to announce that its shareholders have approved the previously announced statutory plan of arrangement under the Canada Business Corporations Act pursuant to whi…

Clementia Pharmaceuticals Inc. Obtains Interim Order for Proposed Transaction With Ipsen S.A. and Enters Into Support and Voting Agreements With Two Additional Significant Shareholders

MONTREAL, March 7, 2019 /PRNewswire/ -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) is pleased to announce that it has obtained an interim order from the Québec Superior Court in connection with the previously announced plan of arrangement pursuant to which a wholly-owned subsidiary of...

SHAREHOLDER ALERT: WeissLaw LLP Investigates Clementia Pharmaceuticals, Inc.

NEW YORK, March 1, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Clementia Pharmaceuticals, Inc. ("CMTA" or the "Company") (NASDAQ: CMTA) in connection with the proposed acquisition of the...

RPT-Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 bln

French healthcare company Ipsen has agreed to buy U.S. peer Clementia Pharmaceuticals in a deal worth up to $1.31 billion, the companies said on Monday, helping to boost Ipsen's portfolio of products treating rare diseases.

Clementia Pharmaceuticals Blogs

Clementia Pharmaceuticals Inc. obtains interim order for proposed transaction with Ipsen S.A. and enters into support and voting agreements with two additional significant shareholders

MONTREAL , March 6, 2019 /PRNewswire/ -  Clementia Pharmaceuticals Inc. (NASDAQ: CMTA) is pleased to announce that it has obtained an interim order from the Québec Superior Court in connection with the previously announced plan of arrangement pursuant to which a wholly-owned subsidiary of Ipsen

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio

Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio Brian.Hoenig@n… Mon, 02/25/2019 - 01:01 Ipsen to Acquire Clementia Pharmaceuticals to Significantly Boost Rare Disease Portfolio February 25, 2019 at 1:00 AM EST This rele…

Clementia Announces the Departure of Chief Commercial Officer

MONTREAL , Nov. 30, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced the departure of Eric Grinstead as the Company’s chief

Clementia to Present at the Evercore ISI HealthCONx Conference

MONTREAL , Nov. 21, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, today announced that Clarissa Desjardins , Ph.D., chief executive officer and

Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers

Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers Content Import Tue, 10/02/2018 - 06:33 Clementia Initiates Phase 1 Clinical Trial of Palovarotene Eye Drop Formulation in Healthy Volunteers October 2, 2018 at 6:30 AM EDT …

Clementia Announces Updated Phase 2 Part B Data on Palovarotene for FOP

Updated 12-Week Flare-Up Data Presented at Mechanistic and Therapeutic Advances in Rare Skeletal Diseases and ASBMR 2018 Company Announces Additional Updated 12-Month WBCT Scan Data Data Continue to Support Treatment Potential of Palovarotene for People with FOP MONTREAL , Sept.
Show more

Clementia Pharmaceuticals Frequently Asked Questions

  • When was Clementia Pharmaceuticals founded?

    Clementia Pharmaceuticals was founded in 2012.

  • Who are Clementia Pharmaceuticals key executives?

    Clementia Pharmaceuticals's key executives are Clarissa Desjardins, Jeff Packman and James M. Roach.

  • Who are Clementia Pharmaceuticals competitors?

    Competitors of Clementia Pharmaceuticals include International Stem Cell Corporation, Innate Pharma and DBV Technologies.

  • Where is Clementia Pharmaceuticals headquarters?

    Clementia Pharmaceuticals headquarters is located at 1000 De La Gauchetière, 1000 Rue de la Gauchetière O #1200, Montréal.

  • Where are Clementia Pharmaceuticals offices?

    Clementia Pharmaceuticals has offices in Montréal and Newton.

  • How many offices does Clementia Pharmaceuticals have?

    Clementia Pharmaceuticals has 2 offices.